scholarly journals The Influence of GPX1 Pro198Leu, CAT C262T and MnSOD Ala16Val Gene Polymorphisms on Susceptibility for Non-Hodgkin Lymphoma and Overall Survival Rate at Five Years from Diagnosis

2019 ◽  
Vol 65 (1) ◽  
pp. 25-30
Author(s):  
Adriana-Stela Cosma ◽  
Cristina Radu ◽  
Alexandra Moldovan ◽  
Alina Bogliș ◽  
George Andrei Crauciuc ◽  
...  
Keyword(s):  
Overall Survival ◽  
Survival Rate ◽  
Hodgkin Lymphoma ◽  
Gene Polymorphisms ◽  
Manganese Superoxide Dismutase ◽  
Control Group ◽  
Overall Survival Rate ◽  
Glutathione Peroxidase 1 ◽  
Non Hodgkin Lymphoma ◽  
Number Of Patients

AbstractObjective: The aim of the current study was to investigate possible associations between catalase C262T (CAT C262T), glutathione peroxidase 1 Pro198Leu (GPX1 Pro198Leu), manganese superoxide dismutase Ala16Val (MnSOD Ala16Val) gene polymorphisms and non-Hodgkin Lymphoma risk (NHL) in a Romanian population and the five-year overall survival rate of the NHL patients.Methods: We included in this case-control study 406 individuals, divided into two groups: the control group (n=315) and the patients group (n=91). The DNA was extracted from peripheral blood and amplified using specific techniques.Results: The variant homozygous genotype of GPX1 Pro198Leu represents a risk factor for NHL development and no associations regarding the risk for NHL were found for MnSOD Ala16Val and CAT C262T gene polymorphisms. Two of the studied polymorphisms were associated with the overall survival rate thus: negative association regarding MnSOD Ala16Val, associated with higher overall survival rate and a positive one regarding CAT C262T, associated with lower overall survival rate.Conclusions: According to our results, the mentioned polymorphisms may be considered as susceptible markers of the five-year overall survival rate for NHL patients. Future studies with a larger number of patients are needed to confirm our results.

scholarly journals Improved Outcome of Relapsed or Refractory Pediatric B-Cell Non-Hodgkin Lymphoma in Japan

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5078-5078
Author(s):  
Tomoo Osumi ◽  
Tetsuya Mori ◽  
Naoto Fujita ◽  
Akiko M. Saito ◽  
Atsuko Nakazawa ◽  
...  
Keyword(s):  
Overall Survival ◽  
Survival Rate ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Salvage Therapy ◽  
Combined Treatment ◽  
B Cell Lymphoma ◽  
Overall Survival Rate ◽  
Hematopoietic Stem ◽  
Non Hodgkin Lymphoma

Abstract Introduction Relapsed or refractory pediatric B-cell non-Hodgkin lymphoma (B-NHL) has been reported to be extremely difficult to cure. We previously conducted a retrospective study of pediatric relapsed or refractory B-NHL in Japan between 1996 and 2004 and found that the four-year overall survival rate was only 20.5% (Fujita N. e al. PBC. 2008). Rituximab, a chimeric anti-CD20 monoclonal antibody, is expected to be effective in improving the prognosis of pediatric relapsed or refractory B-NHL and was approved for use in 2003 in Japan. Here, we retrospectively assessed the treatment and prognosis of pediatric relapsed or refractory pediatric B-NHL in the rituximab era in Japan. Methods We collected relapsed pediatric B-NHL cases from patients enrolled in our current study, JPLSG B-NHL03 study, which was the first nationwide multicenter trial for newly diagnosed pediatric B-NHL. We collected information on treatment and outcome after induction failure or relapse. Results In 33 patients enrolled this study, the median age at diagnosis was 9.7 years and male predominance was observed. Nine cases were pathologically subclassified initially as diffuse large B-cell lymphoma, 11 as Burkitt lymphoma, 11 as Burkitt Leukemia and two as others. According to initial Murphy staging, most cases were in the advanced stage. The most common site of relapse was abdomen (8 cases), followed by bone marrow (8 cases) and central nervous system (7 cases). Twenty-three cases relapsed in one site while 10 did so in multiple sites. Among them, 20 relapsed within six months after initial diagnosis. Among them, 28 patients received some rituximab combined treatment as salvage therapy. R-ICE (rituximab, ifosfamide, carboplatin and etoposide) regimen was the most popular and used in 22 patients as first-line salvage therapy. As a result, 22 patients (66.7%) achieved complete remission (CR) by some salvage therapy. 23 received hematopoietic stem cell transplantation (HSCT). Their 5-year overall survival rate was 48.5%, which was far more superior to both our previous study (Figure 1) and another on relapsed or refractory B-NHL in childhood. In risk factor analysis for survival, rituximab combined treatment and HSCT did not influence the outcome, but achievement of CR after salvage treatment resulted in significantly better survival (68.2% vs 9.1%, p=0.001). These results suggest that the advent of rituximab induced an improvement of CR rate for relapsed paediatric B-NHL, which resulted in an improvement of the survival rate. Conclusion In conclusion, the prognosis of the pediatric relapsed or refractory B-NHL in a Japanese cohort remained poor but is showing improvement in the rituximab era. Disclosures No relevant conflicts of interest to declare.

Comparative analysis of characteristics, survival trends, and associated malignancies of B-cell and T-cell prolymphocytic leukemia: A surveillance, epidemiology, and end results (SEER) based study1998 to 2016.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 7558-7558
Author(s):  
Doaa Attia ◽  
Sara Aly Attia
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
T Cell ◽  
B Cell ◽  
Survival Time ◽  
Hodgkin Lymphoma ◽  
Median Survival ◽  
Prolymphocytic Leukemia ◽  
Non Hodgkin Lymphoma

7558 Background: Prolymphocytic leukemia (PLL) compromises two subsets; B-cell and T-cell, accounting for less than 2% of mature lymphocytic leukemia. Both of them are rare lymphoid neoplasms with a very aggressive clinical course and poor prognosis. Methods: We used SEER program dataset between 1998 and 2016. We divided the patients into 2 groups: B-PLL and T-PLL and identified them using ‘ICD-O-3 histology recode: 9833/3 and 9834/3 respectively. We used SPSS software (version 26, IBM, NY, USA) to calculate overall survival using Kaplan-Meier methods and compare the survival between the two subtypes using the log-rank test. We also used multivariable covariate-adjust cox models to determine the impact of age, sex, race, cause of death, and associated primary malignancies on survival in both types. Results: A retrospective cohort study of 783 patients (295 B-PLL and 488 T-PLL) with overall survival rate of 22.5% (30.2% B-PLL and 18% T-PLL). The overall median survival for PLL was 16 months (95 CI, 13.745-18.255). The median survival of B-PLL (25 months, 95%CI, 15.733-34.267) was much better than T-PLL (14 months, 95%CI, 11.922-16.078). The mean age was 68.7±15.3. Patient age was an independent factor in determining the survival and inversely associated with survival time in both types (p < 0.0001). The survival rate was worst ) among age groups older than 79, between 70-79 years (8.9%, 18.9%) respectively. Although white male patients were more affected in both types, neither sex nor race significantly affected survival (P 0.554, 0.062 respectively). 64.7% of PLL patients died due to cancer. Patients with cancer-related death had significantly shorter survival time in both T-PLL group (HR = 0.351, 95% CI 0.241-0.512) and B-PLL group (HR = 0.682, 95% CI 0.491-0.945). We also found that 24.4% of B-PLL and 19% of T-PLL patients have another associated primary malignancy. Among hematological malignancies, non-hodgkin lymphoma was the commonest. Although associated solid tumors were less common, Prostate cancer and breast cancer were the commonest for both types and lung/bronchus malignancies were more associated with T-PLL. Conclusions: T-PLL subtype has worse prognosis. Age is the most important independent predictor of survival in both types. Although most of affected patients were white males, race and gender have no impact on survival. Non-hodgkin lymphoma is the commonest primary associated malignancy followed by breast and prostate cancer in both types.

scholarly journals Experience of Hepatocellular Cancer Therapy with Multikinase Inhibitors in the Republic of Bashkortostan

2020 ◽  
Vol 10 (3) ◽  
pp. 183-189
Author(s):  
Sh. Kh. Gantsev ◽  
O. N. Lipatov ◽  
K. V. Menshikov ◽  
D. S. Tursumetov ◽  
Kh. S. Saydulaeva
Keyword(s):  
Overall Survival ◽  
Chronic Hepatitis ◽  
Survival Rate ◽  
Survival Rates ◽  
Elevated Serum ◽  
Malignant Neoplasm ◽  
Progression Free Survival ◽  
Control Group ◽  
Overall Survival Rate ◽  
Free Survival

Introduction. Hepatocellular carcinoma (HCC) is the most common primary malignant neoplasm of the liver. During the early stages, HCC is asymptomatic, which makes X-ray examination a particularly important diagnostic tool. According to WHO data, the mortality rate from HCC was 782,000 in 2018. HCC is associated with a number of risk factors: a high viral load, liver cirrhosis, detected HBeAg and elevated serum HBsAg levels. Inhibitors of tyrosine kinase receptors increase the overall survival and progression-free survival rates in patients with metastatic HCC. In this article, we conduct an analysis of results of the REFLECT study obtained for Russian patients by the Republican Clinical Oncological Dispensary, Ufa.Materials and methods. The experimental group included 9 patients (52.9%) receiving Lenvatinib. The control group included 8 patients (47.1%)) underwent therapy with Sorafenib at a dose of 800 mg per day 7 (41.17%) patients had a history of chronic hepatitis, of which hepatitis B and chronic hepatitis C was confirmed in 6 and 1 cases, respectively.Results and discussion. Over the period from 2017 up to the present, progression-free survival was observed in three patients (17.6%), of which 2 and 1 received Lenvatinib and Sorafenib, respectively. Overall survival was 10.5 months. The median overall survival rate in the experimental and control groups was 9.8 and 11.2 months, respectively. These parameters are considered comparable, provided that the sample was small.Conclusions. The use of Lenvatinib demonstrated the efficacy comparable to that of Sorafenib in terms of the overall survival rate in patients with inoperable HCC. Lenvatinib allowed statistically and clinically significant improvement in the progression-free survival and time to progression to be achieved. 

Clinicopathologic Characteristics of Malignant Mesotheliomas Arising in Patients With a History of Radiation for Hodgkin and Non-Hodgkin Lymphoma

2013 ◽  
Vol 31 (36) ◽  
pp. 4544-4549 ◽  
Author(s):  
Lucian R. Chirieac ◽  
Justine A. Barletta ◽  
Beow Y. Yeap ◽  
William G. Richards ◽  
Tamara Tilleman ◽  
...  
Keyword(s):  
Overall Survival ◽  
Hodgkin Lymphoma ◽  
Signet Ring Cell ◽  
Control Group ◽  
Clinicopathologic Characteristics ◽  
Non Hodgkin Lymphoma ◽  
Signet Ring ◽  
History Of ◽  
Ring Cell ◽  
Diffuse Malignant Mesothelioma

Purpose Studies have reported an association between pleural diffuse malignant mesothelioma (PDMM) and chest radiation for lymphoma. The clinicopathologic characteristics of malignant mesotheliomas arising in these patients have not been established. Patients and Methods We studied 1,618 consecutive patients diagnosed with pleural PDMM from July 1993 to February 2008 and identified patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. We evaluated the histology in the surgical resection specimens and compared clinicopathologic features with overall survival. Results We identified 22 patients who developed PDMM after chest radiation as part of their treatment for lymphoma (mean latency time, 21.4 years; 95% CI, 17.0 to 25.8 years). Asbestos bodies in lymphoma-associated PDMM were lower than in asbestos-associated PDMM (median count, 15 v 325 bodies, respectively; P < .001) and similar to an unexposed control group (median count, 15 v 10 bodies, respectively; P = .6). Seventeen lymphoma-associated PDMMs (77%) were epithelioid and five (23%) were biphasic. Seven PDMMs (32%) had unusual histologies (pleomorphic, myxoid, clear cell, and signet ring cell). Patients with lymphoma-associated PDMM were younger than patients with asbestos-associated PDMM (median age, 45 v 64 years, respectively; P < .001) and had a significantly longer overall survival time (median, 32.5 v 12.7 months, respectively; P = .018). In multivariate analysis, independent favorable predictors for overall survival were history of prior radiation (P = .022), female sex (P < .001), age ≤ 65 years (P = .005), cytoreductive surgery (P < .001), and epithelioid histology (P < .001). Conclusion Patients with lymphoma-associated PDMM are likely to have unusual histologic features, are significantly younger, and seem to have a longer overall survival compared with patients with asbestos-associated PDMM.

scholarly journals Expression and Diagnostic Value of miR-497 and miR-1246 in Hepatocellular Carcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Shuying Chen ◽  
Zile Fu ◽  
Shuzhan Wen ◽  
Xiaoyi Yang ◽  
Chengxuan Yu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Survival Rate ◽  
Target Genes ◽  
Expression Level ◽  
Control Group ◽  
Overall Survival Rate ◽  
Expression Levels ◽  
Preoperative Serum ◽  
Low Expression

ObjectiveSerum microRNAs (miRNAs) may serve as biomarkers in various cancers. Our study aims to explore the roles of miR-497 and miR-1246 in hepatocellular carcinoma (HCC).MethodsThe expression levels of miR-497 and miR-1246 were measured by RT-PCR. A correlation analysis was conducted between the expression levels of miR-497 and miR-1246 and clinicopathological characteristics of patients. The receiver operating characteristic (ROC) curve was applied to evaluate the diagnostic efficacy in HCC. In addition, bioinformatics tools were also utilized to predict the potential targets of miR-497 and miR-1246.ResultsThe expression level of miR-497 in HCC was significantly down-regulated compared with the control group while the miR-1246 revealed a significantly higher expression level in HCC. There was a significant correlation demonstrated between the expression levels of miR-497 and miR-1246 in preoperative serum of HCC and the differentiation degree, Tumor Node Metastasis (TNM) classification, and metastasis. The expression levels of serum miR-497 and miR-1246 were significantly associated with the diagnosis, prognosis, and overall survival rate of patients with HCC. Moreover, the potential target genes of miR-497 in HCC include ARL2, UBE2Q1, PHF19, APLN, CHEK1, CASK, SUCO, CCNE1, and KIF23. The low expression of these nine genes is associated with a better prognosis of HCC patients. AUTS2 is a novel target gene of miR-1246, and its low expression is significantly related to the low overall survival rate of HCC patients.ConclusionsmiR-497 and miR-1246 are possibly involved in the progression of HCC by regulating target genes, respectively, and could serve as biomarkers in HCC.

Outpatient fractionated ICE protocol in relapsed/refractory lymphomas: Efficacy and safety

2021 ◽  
pp. 107815522098806
Author(s):  
Reyad Dada ◽  
Ehab Mosaad Abdelghani ◽  
Tarek Boubakra ◽  
Jaweed Vayani ◽  
Osama Yousof ◽  
...  
Keyword(s):  
Survival Rate ◽  
Hodgkin Lymphoma ◽  
Care Center ◽  
Tertiary Care ◽  
Free Survival ◽  
Non Hodgkin Lymphoma ◽  
Number Of Patients ◽  
Refractory Lymphoma ◽  
Grade 3 ◽  
Favorable Safety

Methods In this retrospective trial, we analyzed data of patients with relapsed/refractory lymphoma who received outpatient fractionated ICE between 2011-2017 at a tertiary care center. The three weekly ICE protocol consisted of: ifosfamide 1500 mg/m2 infused over 2 h on days 1–3, carboplatin (5 AUC) on day 1, and etoposide 100 mg/m2 on days 1–3. Rituximab 375 mg/m2 was given to patients with CD20 positive B cell Non-Hodgkin lymphoma. Results Total of 89 patients were included in this research project. Majority of patients had Hodgkin lymphoma (64%). Mean number of ICE cycles received was 2.5. Complete remission and partial remission rates for primary refractory (62.9%) and non-primary refractory (36.4%) disease were 10.5% and 26.3% versus 41.9% and 29.0% respectively. Event free survival rate was 14.5 months (95% CI 7.7–28.0) and overall survival rate 88.7 months (95% CI 48.1–NR). Grade 3 hematological toxicities were documented in 19.1% of patients with 10.1% experiencing neutropenia and 9% thrombocytopenia. 5.6% had febrile neutropenia. Conclusions Our study included, to our knowledge, the largest number of patients treated with outpatient fractionated ICE. Results demonstrated that this regimen might be a reasonable replacement for classic ICE regimen in many patients with lymphoma. It has a favorable safety profile. However, patients with primary refractory lymphomas need more effective regimens.

scholarly journals The importance of intensive chemotherapy for advanced Hodgkin lymphoma in children

2020 ◽  
Vol 3 (2) ◽  
pp. 149-154
Author(s):  
E.S. Belyaeva ◽  
◽  
N.A. Susuleva ◽  
T.T. Valiev ◽  
◽  
...  
Keyword(s):  
Overall Survival ◽  
Survival Rate ◽  
Treatment Outcomes ◽  
Hodgkin Lymphoma ◽  
Survival Rates ◽  
Complete Response ◽  
High Survival ◽  
Overall Survival Rate ◽  
Large Tumor ◽  
Free Survival

Background: currently, Hodgkin lymphoma (HL) in children is characterized by excellent treatment outcomes due to the use of modern risk-adapted treatment strategies. Overall survival rate for HL is more than 90%, therefore, further development of therapeutic protocols should be focused on minimizing toxicity and late adverse reactions.Aim: to improve HL treatment outcomes in children by intensive risk-adapted chemotherapy and personalized approach to radiotherapy.Patients and Methods: 134 children with HL stage II (with large tumor mass) to IV diagnosed for the first time were enrolled in the study. Morphological immunological verification of the diagnosis was performed in all children. HL was staged using imaging techniques (i.e., gallium-67 or technetium-99 imaging, computed tomography, positron-emission tomography). HL-2007 SRC POH protocol based on escBEACOPP regimen was applied. To assess treatment efficacy, overall, relapse-free, and event-free survival rates were calculated. Statistical analysis was performed using SPSS19.0 software.Results: risk-adapted treatment based on the terms of complete remission achievement has provided high survival rates even in advanced HL stages. Thus, 14-year overall survival rate was 97.7±1.3%, relapse-free survival rate 92.2±2.4%, and event-free survival rate 90.7±2.6%. Among late adverse reactions, secondary tumors (i.e., breast cancer after mediastinal radiotherapy) were reported. In girls with early (after 4 chemotherapy courses) complete response, we were able to avoid radiotherapy which was not associated with poorer treatment outcomes (overall survival rate was 98.5±1.5%).Conclusion: personalized HL treatment using HL-2007 SRC POH regimen provides high survival rate in most children and the avoidance of radiotherapy in girls with early complete response without negative impact on treatment outcomes. Our findings demonstrate that this therapeutic regimen can be recommended for children with advanced HL and large tumor mass at baseline.Keywords: Hodgkin lymphoma, chemotherapy, radiotherapy, children, survival.For citation: Belyaeva E.S., Susuleva N.A., Valiev T.T. The importance of intensive chemotherapy for advanced Hodgkin lymphoma in children. Russian Journal of Woman and Child Health. 2020;3(2):149–154. DOI: 10.32364/2618-8430-2020-3-2-149-154.

scholarly journals Mesenchymal Stem Cell Therapy in Decompensated Liver Cirrhosis: A Long-Term Follow-up Analysis of the Randomized Controlled Clinical Trial

2021 ◽  
Author(s):  
Ming Shi ◽  
Yuan-Yuan Li ◽  
Ruo-Nan Xu ◽  
Fan-Ping Meng ◽  
Shuang-Jie Yu ◽  
...  
Keyword(s):  
Overall Survival ◽  
Survival Rate ◽  
Liver Function ◽  
Treated Group ◽  
Control Group ◽  
Overall Survival Rate ◽  
Decompensated Liver Cirrhosis ◽  
Randomized Controlled

Abstract BackgroundMesenchymal stem cells (MSC) infusion was reported to improve liver function in patients with decompensated liver cirrhosis (DLC), however, whether the medication can improve outcome of these patients is poorly understand.MethodsThis prospective, open-labeled, randomized controlled study enrolled 219 patients with HBV-related DLC who were divided into control group (n=111) and umbilical cord-derived MSC (UC-MSC) treated group (n=108), then all of them received a follow-up check from October 2010 to October 2017. The treated patients received three times of UC-MSC infusions at 4-week intervals plus conventional treatment that was only used for control group. The overall survival rate and HCC-free survial rate were calculated as primary endpoints and the liver function and adverse events associated with the medication were also evaluated.ResultsDuring the follow-up check period from 13th to 75th months, there was a significantly higher overall survival rate in the treated group than the control group, while the difference of the hepatocellular carcinoma event-free survival rate between the treated and control groups was not observed during the 75-month follow-up. UC-MSC treatment markedly improved liver function, as indicated by the levels of serum albumin, prothrombin activity, cholinesterase, and total bilirubin during 48 weeks of follow-up. No significant side effects or treatment-related complications were observed in the UC-MSC group.ConclusionsTherapy of UC-MSC is not only well tolerated, but also significantly improves long-term survival rate, as well as the liver function in patients with DLC. UC-MSC medication, therefore, might present a novel therapeutic approach for the disease.

scholarly journals Expression of CENPE and its prognostic role in non-small cell lung cancer

Open Medicine ◽  
2019 ◽  
Vol 14 (1) ◽  
pp. 497-502 ◽  
Author(s):  
Xuezhi Hao ◽  
Tao Qu
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
High Expression ◽  
Control Group ◽  
Overall Survival Rate ◽  
Small Cell Lung

AbstractBackgroundNon-small cell lung cancer (NSCLC) is one of the most important causes of death worldwide. Most patients are diagnosed in the advanced stage and have a poor prognosis. This study was to investigate the expression and significance of CENPE in NSCLC.MethodCollecting information about CENPE in the Oncoming database, and perform a further analysis of the data in the current database to conduct a meta-analysis for its functional role in NSCLC. Patient life cycle analysis using Kaplan-Meier Plotter and GEPIA databases are used to perform patient survival analysis.ResultA total of 12 studies involved the expression of CENPE in NSCLC cancer tissues and normal tissues, including 1195 samples. CENPE was highly expressed in NSCLC cell carcinoma compared with the control group (P < 0.05). Moreover, the expression of CENPE was correlated with the overall survival rate of CENPE. The overall survival rate of patients with high expression of CENPE was poor, and the prognosis of patients with low expression of CENPE was better (P<0.05).ConclusionWe propose high expression of CENPE in NSLCL tissue is related to the prognosis of NSCLC, which may provide important basis for the development of tumor drugs.

scholarly journals The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review

2021 ◽  
Vol 28 ◽  
pp. 107327482199743
Author(s):  
Ke Chen ◽  
Xiao Wang ◽  
Liu Yang ◽  
Zheling Chen
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Survival Rate ◽  
Meta Analysis ◽  
Response Rates ◽  
Control Group ◽  
Term Survival ◽  
Long Term Survival ◽  
And Control

Background: Treatment options for advanced gastric esophageal cancer are quite limited. Chemotherapy is unavoidable at certain stages, and research on targeted therapies has mostly failed. The advent of immunotherapy has brought hope for the treatment of advanced gastric esophageal cancer. The aim of the study was to analyze the safety of anti-PD-1/PD-L1 immunotherapy and the long-term survival of patients who were diagnosed as gastric esophageal cancer and received anti-PD-1/PD-L1 immunotherapy. Method: Studies on anti-PD-1/PD-L1 immunotherapy of advanced gastric esophageal cancer published before February 1, 2020 were searched online. The survival (e.g. 6-month overall survival, 12-month overall survival (OS), progression-free survival (PFS), objective response rates (ORR)) and adverse effects of immunotherapy were compared to that of control therapy (physician’s choice of therapy). Results: After screening 185 studies, 4 comparative cohort studies which reported the long-term survival of patients receiving immunotherapy were included. Compared to control group, the 12-month survival (OR = 1.67, 95% CI: 1.31 to 2.12, P < 0.0001) and 18-month survival (OR = 1.98, 95% CI: 1.39 to 2.81, P = 0.0001) were significantly longer in immunotherapy group. The 3-month survival rate (OR = 1.05, 95% CI: 0.36 to 3.06, P = 0.92) and 18-month survival rate (OR = 1.44, 95% CI: 0.98 to 2.12, P = 0.07) were not significantly different between immunotherapy group and control group. The ORR were not significantly different between immunotherapy group and control group (OR = 1.54, 95% CI: 0.65 to 3.66, P = 0.01). Meta-analysis pointed out that in the PD-L1 CPS ≥10 sub group population, the immunotherapy could obviously benefit the patients in tumor response rates (OR = 3.80, 95% CI: 1.89 to 7.61, P = 0.0002). Conclusion: For the treatment of advanced gastric esophageal cancer, the therapeutic efficacy of anti-PD-1/PD-L1 immunotherapy was superior to that of chemotherapy or palliative care.

Sign in / Sign up

Export Citation Format

Share Document